Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 13, 2025, titled "Closure of USFDA inspection at Zydus formulation manufacturing plant at SEZ II, Ahmedabad".
Press Release Aug 13 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the closure of a USFDA inspection at its formulation manufacturing plant in Ahmedabad. The inspection was a Pre-Approval Inspection for three products and concluded with no observations. This announcement serves as a disclosure in accordance with regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Aug 12 2025
- Press Release Aug 11 2025
- Press Release Aug 08 2025
- Press Release Aug 07 2025
- Press Release Jul 29 2025
Later from Zydus Lifesciences
- Press Release 20-08-2025 Newspaperadvertisement20082025
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
- Press Release Aug 29 2025
- Press Release Sep 02 2025
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences